Cargando…
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia
BACKGROUND: Approximately 5% of all breast cancers can be attributed to a mutation in the BRCA1 or BRCA2 gene. The genetic component of breast cancer in Colombia has been, for the most part, studied on cases from the Bogota region. Five different founder mutations were in two studies of breast cance...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998735/ https://www.ncbi.nlm.nih.gov/pubmed/24742220 http://dx.doi.org/10.1186/1897-4287-12-11 |
_version_ | 1782313408350126080 |
---|---|
author | Hernández, Julián Esteban Londoño Llacuachaqui, Marcia Palacio, Gonzalo Vásquez Figueroa, Juan David Madrid, Jorge Lema, Mauricio Royer, Robert Li, Song Larson, Garrett Weitzel, Jeffrey N Narod, Steven A |
author_facet | Hernández, Julián Esteban Londoño Llacuachaqui, Marcia Palacio, Gonzalo Vásquez Figueroa, Juan David Madrid, Jorge Lema, Mauricio Royer, Robert Li, Song Larson, Garrett Weitzel, Jeffrey N Narod, Steven A |
author_sort | Hernández, Julián Esteban Londoño |
collection | PubMed |
description | BACKGROUND: Approximately 5% of all breast cancers can be attributed to a mutation in the BRCA1 or BRCA2 gene. The genetic component of breast cancer in Colombia has been, for the most part, studied on cases from the Bogota region. Five different founder mutations were in two studies of breast cancer patients in the Bogota region. It is important that the frequency of mutations be established among unselected cases of breast cancer of other regions of Colombia in order to estimate the genetic burden of this cancer in Colombia and to plan genetic services. The aim of this study was to establish the mutation frequencies of the BRCA genes in breast cancer patients unselected for family history or age, from Medellin, Colombia. METHODS: We enrolled 280 unselected women with breast cancer from a large public hospital in Medellin, Colombia. A detailed family history from each patient and a blood sample was obtained and processed for DNA analysis. Mutations in BRCA1 and BRCA2 were sought using a combination of techniques including a panel of recurrent Hispanic BRCA mutations which consists of fifty BRCA1 mutations and forty-six BRCA2 mutations, including the five recurrent Colombian BRCA mutations. All mutations were confirmed by direct sequencing. RESULTS: Genetic testing was successfully completed for 244 of the 280 cases (87%). Among the 244 cases, three deleterious mutations were identified (two in BRCA1 and one in BRCA2) representing 1.2% of the total. The average age of breast cancer in the mutation-positive cases was 34 years. The two BRCA1 mutations were known founder mutations (3450del4 in exon 11 and A1708E in exon 18). The BRCA2 mutation was in exon 11 (5844del5) and has not been previously reported in individuals of Colombian descent. Among the three mutation-positive families was a breast cancer family and two families with no history of breast or ovarian cancer. CONCLUSION: The frequency of BRCA mutations in unselected breast cancer cases from the Medellin region of Colombia is low and is approximately 1.2%. |
format | Online Article Text |
id | pubmed-3998735 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-39987352014-04-25 Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia Hernández, Julián Esteban Londoño Llacuachaqui, Marcia Palacio, Gonzalo Vásquez Figueroa, Juan David Madrid, Jorge Lema, Mauricio Royer, Robert Li, Song Larson, Garrett Weitzel, Jeffrey N Narod, Steven A Hered Cancer Clin Pract Research BACKGROUND: Approximately 5% of all breast cancers can be attributed to a mutation in the BRCA1 or BRCA2 gene. The genetic component of breast cancer in Colombia has been, for the most part, studied on cases from the Bogota region. Five different founder mutations were in two studies of breast cancer patients in the Bogota region. It is important that the frequency of mutations be established among unselected cases of breast cancer of other regions of Colombia in order to estimate the genetic burden of this cancer in Colombia and to plan genetic services. The aim of this study was to establish the mutation frequencies of the BRCA genes in breast cancer patients unselected for family history or age, from Medellin, Colombia. METHODS: We enrolled 280 unselected women with breast cancer from a large public hospital in Medellin, Colombia. A detailed family history from each patient and a blood sample was obtained and processed for DNA analysis. Mutations in BRCA1 and BRCA2 were sought using a combination of techniques including a panel of recurrent Hispanic BRCA mutations which consists of fifty BRCA1 mutations and forty-six BRCA2 mutations, including the five recurrent Colombian BRCA mutations. All mutations were confirmed by direct sequencing. RESULTS: Genetic testing was successfully completed for 244 of the 280 cases (87%). Among the 244 cases, three deleterious mutations were identified (two in BRCA1 and one in BRCA2) representing 1.2% of the total. The average age of breast cancer in the mutation-positive cases was 34 years. The two BRCA1 mutations were known founder mutations (3450del4 in exon 11 and A1708E in exon 18). The BRCA2 mutation was in exon 11 (5844del5) and has not been previously reported in individuals of Colombian descent. Among the three mutation-positive families was a breast cancer family and two families with no history of breast or ovarian cancer. CONCLUSION: The frequency of BRCA mutations in unselected breast cancer cases from the Medellin region of Colombia is low and is approximately 1.2%. BioMed Central 2014-04-17 /pmc/articles/PMC3998735/ /pubmed/24742220 http://dx.doi.org/10.1186/1897-4287-12-11 Text en Copyright © 2014 Hernández et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Hernández, Julián Esteban Londoño Llacuachaqui, Marcia Palacio, Gonzalo Vásquez Figueroa, Juan David Madrid, Jorge Lema, Mauricio Royer, Robert Li, Song Larson, Garrett Weitzel, Jeffrey N Narod, Steven A Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia |
title | Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia |
title_full | Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia |
title_fullStr | Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia |
title_full_unstemmed | Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia |
title_short | Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia |
title_sort | prevalence of brca1 and brca2 mutations in unselected breast cancer patients from medellín, colombia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998735/ https://www.ncbi.nlm.nih.gov/pubmed/24742220 http://dx.doi.org/10.1186/1897-4287-12-11 |
work_keys_str_mv | AT hernandezjulianestebanlondono prevalenceofbrca1andbrca2mutationsinunselectedbreastcancerpatientsfrommedellincolombia AT llacuachaquimarcia prevalenceofbrca1andbrca2mutationsinunselectedbreastcancerpatientsfrommedellincolombia AT palaciogonzalovasquez prevalenceofbrca1andbrca2mutationsinunselectedbreastcancerpatientsfrommedellincolombia AT figueroajuandavid prevalenceofbrca1andbrca2mutationsinunselectedbreastcancerpatientsfrommedellincolombia AT madridjorge prevalenceofbrca1andbrca2mutationsinunselectedbreastcancerpatientsfrommedellincolombia AT lemamauricio prevalenceofbrca1andbrca2mutationsinunselectedbreastcancerpatientsfrommedellincolombia AT royerrobert prevalenceofbrca1andbrca2mutationsinunselectedbreastcancerpatientsfrommedellincolombia AT lisong prevalenceofbrca1andbrca2mutationsinunselectedbreastcancerpatientsfrommedellincolombia AT larsongarrett prevalenceofbrca1andbrca2mutationsinunselectedbreastcancerpatientsfrommedellincolombia AT weitzeljeffreyn prevalenceofbrca1andbrca2mutationsinunselectedbreastcancerpatientsfrommedellincolombia AT narodstevena prevalenceofbrca1andbrca2mutationsinunselectedbreastcancerpatientsfrommedellincolombia |